title: The reduction of left ventricular hypertrophy after renal transplantation is not influenced by the immunosuppressive regimen.
abstract: BACKGROUND
  Cardiovascular (CV) disease is the first cause of death after kidney transplantation. Left ventricular hypertrophy (LVH) is one of the main CV risk factors. It has been reported that the antiproliferative properties of everolimus (EVE) treatment may decrease left ventricular mass. The aim of this study was to evaluate the evolution of LVH in two groups of kidney transplant recipients receiving immunosuppressive treatment with low-dose calcineurin inhibitor (CNI) + EVE or CNI + mycophenolate mofetil (MMF).
  
  
  METHODS
  We evaluated 104 patients of mean age 47.5 ± 13.1 years who underwent kidney transplantation between January 2006 and December 2009 pretransplant by echocardiography, which was repeated every year for 3 years during which all patients continued the initial therapy. Over the 3-year period 76 subjects were treated with MMF, and 28 with EVE. We recorded left ventricular end-diastolic diameter (LVEDD), interventricular septum thickness in diastole (IVSTD), left ventricular posterior wall thickness in diastole (LVPWD), left ventricular end-diastolic volume and end-systolic volume during the follow-up echocardiographic evaluations.
  
  
  RESULTS
  No differences in the evolution of the echocardiographic parameters were observed between the two groups-MMF versus EVE group: LVEDD, 50.3 ± 5.1 versus 51.2 ± 6.7 mm; IVSTD, 11.2 ± 1.9 versus 11.3 ± 2 mm; LVPWD, 10.2 ± 1.9 versus 10.5 ± 1.7 mm; relative wall thickness, 0.041 ± 0.08 versus 0.42 ± 0.08; ejection fraction, 63 ± 6% versus 61 ± 5%; and left ventricular mass index, 113 ± 28.9 versus 121.9 ± 39.4 g/m(2), respectively. Compared with pretransplant echocardiographic evaluations, similar reductions in left ventricular mass index were noted in both groups after transplantation.
  
  
  CONCLUSIONS
  We observed that after renal transplantation there was a reduction of the LVH respect to the pretransplant dialytic status. The two immunosuppressive regimen did not influence the evolution of post-transplant LVH.
authors.affiliation: Department of Surgical Science, Renal Transplant Unit, Catholic University, Rome, Italy.
authors.forename: M P
authors.initials: MP
authors.lastname: Salerno
authors.forename: E
authors.initials: E
authors.lastname: Rossi
authors.forename: E
authors.initials: E
authors.lastname: Favi
authors.forename: J A
authors.initials: JA
authors.lastname: Pedroso
authors.forename: G
authors.initials: G
authors.lastname: Spagnoletti
authors.forename: J
authors.initials: J
authors.lastname: Romagnoli
authors.forename: F
authors.initials: F
authors.lastname: Citterio
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000628:therapy*; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D007166:Immunosuppressive Agents